If Amarantus does a 20:1 RS, that would at least get us to a position to uplist, right? What would be the risk associated with that?

I understand the dynamics of uplisting as statistically a bad idea, but if the ratio were small enough and we got off the OTC, it would appear to be a win win.

Dunno....just looking for other opinions.